ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2013
Biomarker discovery for heterogeneous diseases.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Is there a maternal blood biomarker that can predict spontaneous preterm birth prior to labour onset? A systematic review.PloS one · 2022Pooled it
- Article
- Innovations in biomarker stratification for precision oncology.Clinical and experimental medicine · 2026Review
- Article
- Article
- BioMapAI: Artificial Intelligence Multi-Omics Modeling of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome.bioRxiv : the preprint server for biology · 2025Article
- Editorial: Participant characteristics and biological markers for endometriosis diagnosis or prediction of treatment response.Frontiers in reproductive health · 2024Article
- Article
- Comparative Analysis of Antimicrobial Antibodies between Mild and Severe COVID-19.Microbiology spectrum · 2023Article
- Plasma autoantibodies IgG and IgM to PD1/PDL1 as potential biomarkers and risk factors of lung cancer.Journal of cancer research and clinical oncology · 2023Article
- Heterogeneous expression of alternatively spliced lncRNA mediates vascular smooth cell plasticity.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Decentralised clinical trials in multiple sclerosis research.Multiple sclerosis (Houndmills, Basingstoke, England) · 2023Review
- Unraveling patient heterogeneity in complex diseases through individualized co-expression networks: a perspective.Frontiers in genetics · 2023Article
- Multibiomarker approach to assess the magnitude of occupational exposure and effects induced by a mixture of metals.Toxicology and applied pharmacology · 2021Article
- Lithographic Processes for the Scalable Fabrication of Micro- and Nanostructures for Biochips and Biosensors.ACS sensors · 2021Review
- HaloTag-based conjugation of proteins to barcoding-oligonucleotides.Nucleic acids research · 2020Article
- Measurement of Organ-Specific and Acute-Phase Blood Protein Levels in Early Lyme Disease.Journal of proteome research · 2020Article
- Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients.Theranostics · 2020Article
- Tumor-associated autoantibodies in combination with alpha-fetoprotein for detection of early stage hepatocellular carcinoma.PloS one · 2020Article
- Emerging Technologies and Platforms for the Immunodetection of Multiple Biochemical Markers in Osteoarthritis Research and Therapy.Frontiers in medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundModern genomic and proteomic studies reveal that many diseases are heterogeneous, comprising multiple different subtypes. The common notion that one biomarker can be predictive for all patients may need to be replaced by an understanding that each subtype has its own set of unique biomarkers, affecting how discovery studies are designed and analyzed.
methodsWe used Monte Carlo simulation to measure and compare the performance of eight selection methods with homogeneous and heterogeneous diseases using both single-stage and two-stage designs. We also applied the selection methods in an actual proteomic biomarker screening study of heterogeneous breast cancer cases.
resultsDifferent selection methods were optimal, and more than two-fold larger sample sizes were needed for heterogeneous diseases compared with homogeneous diseases. We also found that for larger studies, two-stage designs can achieve nearly the same statistical power as single-stage designs at significantly reduced cost.
conclusionsWe found that disease heterogeneity profoundly affected biomarker performance. We report sample size requirements and provide guidance on the design and analysis of biomarker discovery studies for both homogeneous and heterogeneous diseases. IMPACT: We have shown that studies to identify biomarkers for the early detection of heterogeneous disease require different statistical selection methods and larger sample sizes than if the disease were homogeneous. These findings provide a methodologic platform for biomarker discovery of heterogeneous diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.